Molecular Characteristics Predict Clinical Outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene

Παρόμοια τεκμήρια

• Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations
  ανά: Janjigian, Yelena Y., κ.ά.
  Έκδοση: (2011)
• Core Needle Lung Biopsy Specimens: Adequacy for EGFR and KRAS Mutational Analysis
  ανά: Solomon, Stephen B., κ.ά.
  Έκδοση: (2010)
• Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
  ανά: Oxnard, Geoffrey R., κ.ά.
  Έκδοση: (2011)
• Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib
  ανά: Zakowski, Maureen F., κ.ά.
  Έκδοση: (2009)
• Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
  ανά: Price, Katharine A., κ.ά.
  Έκδοση: (2010)